Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. [electronic resource]
Producer: 20190311ISSN:- 2050-084X
- Animals
- Antineoplastic Agents -- administration & dosage
- CDC2 Protein Kinase -- antagonists & inhibitors
- Cell Line, Tumor
- Cyclin-Dependent Kinases -- antagonists & inhibitors
- Disease Models, Animal
- Down-Regulation
- Enzyme Inhibitors -- administration & dosage
- Female
- Heterografts
- Humans
- Mice, SCID
- Neoplasm Transplantation
- Ovarian Neoplasms -- drug therapy
- Phenylenediamines -- administration & dosage
- Proto-Oncogene Proteins c-myc -- biosynthesis
- Pyrimidines -- administration & dosage
- Treatment Outcome
- Cyclin-Dependent Kinase-Activating Kinase
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.